Synthon concluded Phase I clinical trial for trastuzumab

March 23, 2012 8:10 AM

Synthon announced yesterday that it has successfully concluded a phase I clinical trial for trastuzumab, a biosimilar to Herceptin, for treatment of breast cancer and gastric cancer.

The company will now initiate a phase III clinical trial for trastuzumab, bringing an affordable alternative for treatment of breast and gastric cancer closer to the market.

All in vitro and in vivo studies conducted so far showed biosimilar behavior of Synthon’s trastuzumab in comparison with the reference product, Herceptin. The outcome of the phase I clinical trial confirmed these results, showing bio-equivalence of Synthon’s trastuzumab to Herceptin.

“Trastuzumab is one of the most advanced biopharmaceutical products of Synthon’s pipeline, and is now ready to go into a confirmatory phase III clinical trial in breast cancer patients,” says Rudy Mareel, CEO Synthon.

“Biosimilars are to Synthon a serious stepping stone towards the development of biosuperior and truly innovative biological products. We are very excited about our growing portfolio of new biological antiproliferative agents that is well positioned next to our biosimilars.”

Continues Mareel: “We are also making significant progress toward our specialty pharmaceuticals strategy, organized around the key therapeutic areas of multiple sclerosis / auto-immune diseases and oncology. We have a significant pipeline under development in these areas, across all our technological platforms of high quality generics, biosimilars and new biological and chemical entities. We are also capitalizing on the strength of our strategy, as a growing number of renowned companies pursue partnerships with Synthon to support our specialty pharma journey. This confirms our belief in our collaborative model and we remain open to research and commercial partnerships.”

Synthon, with headquarters in the Netherlands, is an international pharmaceutical company and working in the field of generic medicines. Synthon has been working in biotechnology since 2007 and is developing into a specialty pharmaceutical company, focusing on the therapeutic areas of auto-immune diseases, multiple sclerosis and oncology.

Source: Synthon press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!